Meenta was born out of the idea that life science and diagnostics could greatly benefit from the technological revolution that has forever changed the way we shop, dine, vacation, and catch a ride. Grounded in technology and sitting at the intersection of supply and demand, the Meenta marketplace brings together the widest array of testing products and laboratory services combined with world-class scientific expertise and clinical oversight all in one place. Meenta exists to completely revolutionize the way the world accesses diagnostic testing and laboratory capabilities. Our vision is to make all of the world’s scientific equipment and clinical tests accessible to everyone.
We are an eclectic group of thinkers and doers who are determined to fix a broken testing industry.
What if testing demand could be distributed in real time like CPU time in the cloud? Why can’t healthcare providers access cutting edge diagnostic tests anytime from anywhere? Why not give doctors and patients unprecedented access to affordable tests that could lead to better outcomes? How come very expensive capital equipment sits idle in labs? Why isn’t excess capacity dynamically available at the click of a mouse? What if testing was never constrained by supply chain issues? Why not horizontally integrate a siloed industry to provide better healthcare?
And then boldly created the answer…
Any Test. Any Time. One Marketplace.
CEO & Founder
Gabor has 20 years of business expertise in the area of genomics and diagnostics spanning some of the best companies in the field including Agilent Technologies and Roche Diagnostics. As founder and Chief Commercial Officer of Parabase Genomics he built the company from the ground up creating the first commercial play in the field of Neonatal Precision Medicine.
CTO & Founder
Boston based entrepreneur and full stack developer with extensive web, mobile, and systems design and development experience. Has extensive experience building development teams, system architecture and managing software through the planning, development and deployment.
Director of Product & Founder
Torrey is Director of Product and a Co-Founder at Meenta. She has worked in global health economics at the Harvard Medical School, WHO, and is a former Peace Corps Volunteer. She holds a master’s degree in global development, International public health from Boston University.
Chief Commercial Officer
Dana has 20 years of commercialization success in Diagnostics and Biotechnology applying in-depth technical knowledge of molecular genetics and clinical informatics to deliver innovative solutions that address unmet customer needs, and is now responsible for developing and executing the commercial strategy at Meenta.
VP of Operations
John is an entrepreneurial operations executive with a proven track record of starting, scaling and expanding operations during periods of rapid growth. Broad Operations expertise including Laboratory Operations, Manufacturing, Supply Chain, QA/QC, Facility Management, Finance and Product Development. He previously established US operations for two highly successful startup diagnostic companies and managed expansion of capacity of each.
Thought leaders and industry experts from genomics to tech.
Chief Strategy Officer, Sequence Bio. Co-Founder and Consulting Chief Commercial Officer, Remedy Bio.
Dr. Leach is an executive leader, scientist, and entrepreneur. Through his career, he has acquired domain expertise in human genomics, big data, A.I., reproductive medicine, aerospace, manufacturing, corporate strategy, and business development. Demonstrating the ability to lead from concept through delivery, Dr. Leach has chaperoned fundamental technologies with and without established applications to successful business endpoints by guiding company architecture, market development and commercialization. Some of his previous roles include Chief Commercial Officer at WuXi NextCode Genomics, Vice President at Complete Genomics, Vice President at deCODE Genetics, and Chief Science Officer and Founder at Teneo Sciences. While at those companies, Dr. Leach created business strategies and successfully led the implementation of genetic analysis technologies for research and clinical diagnostic applications in multiple geopolitical environments. With significant involvement in population-specific and nation-scale discovery biology programs, he has led successful business opportunities in 28 countries around the world. In addition to this, he has gained high-level governance experience during service on several Boards of Directors. Today, Dr. Leach is the Chief Strategy Officer for the International Space Station U.S. National Laboratory, spearheading Low Earth Orbit commercialization by developing a portfolio of basic and applied research programs in public-private partnerships.
Dr. Leach holds a B.S. degree in Biology from Hillsdale College, a Ph.D. in Molecular Biology from Ohio University, was a Fellow in the Division of Experimental Therapeutics at Walter Reed Army Institute of Research for the US Department of Defense and was a Visiting Fellow at the National Cancer Institute of the National Institutes of Health.
Professor, Department of Physiology and Biophysics, Weill Cornell Medicine
Dr. Christopher Mason is a Professor of Physiology, Biophysics, and Genomics at Weill Cornell Medicine and the Director of the WorldQuant Initiative for Quantitative Prediction.His laboratory develops and deploys computational and experimental methodologies to identify the functional genetic elements of the human genome and metagenome. Dr. Mason has won the NIH’s Transformative R01 Award, the NASA Group Achievement Award, the Pershing Square Sohn Cancer Research Alliance Young Investigator award, the Hirschl-Weill-Caulier Career Scientist Award, the Vallee Scholar Award, the CDC Honor Award for Standardization of Clinical Testing, and the WorldQuant Foundation Scholar Award. He was named as one of the “Brilliant Ten” Scientists by Popular Science, featured as a TEDMED speaker, and called “The Genius of Genetics” by 92Y. He has >250 peer-reviewed papers and scholarly works that have been featured on the covers of Nature, Science, Cell, Nature Biotechnology, Nature Microbiology, and Neuron, as well as legal briefs cited by the U.S. District Court and U.S. Supreme Court. Coverage of his work has also appeared on the covers of the Wall Street Journal, New York Times, TIME, The LA Times, and across many media (ABC, NBC, CBS, Fox, CNN, PBS, NASA, NatGeo). He is an inventor on four patents, co-founded five biotechnology start-up companies, and serves as an advisor to 17 others, as well as 3 non-profits. He lives with his daughter and wife in Brooklyn, NY.
Principle, Clinical Innovation, OptimizeRx
Rebecca is a thought leader on Nurse Innovation & Entrepreneurship, experienced nurse executive and entrepreneur, first nurse featured on Ted.com, and inaugural nursing panel at SXSW. Rebecca designed and built the first nurse innovation program in the United States at Northeastern University, that led Rebecca to found SONSIEL, a 501C-3 non-profit, which she serves as President alongside an incredible board of nurse leaders that aims to reposition and redefine the image of nursing across healthcare. In addition, Rebecca sits as an advisory board member on several leading digital health startups and organizations, has co-authored 2 books, founded 3 companies, speaks internationally, and is dedicated and passionate about empowering nurses to be at the forefront of healthcare innovation and entrepreneurship.
Director of Genomic Services Lab, HudsonAlpha Institute
Shawn Levy, PhD, is a faculty investigator and the founding director of the Genomic Services Laboratory (GSL) at the HudsonAlpha Institute for Biotechnology. He serves as executive director of the HudsonAlpha Clinical Services Laboratory, LLC., which he launched in 2014. Levy focuses on the development and application of genomic and bioinformatic technologies and methods to support scientific investigation. His team uses high performance genotyping and sequencing technologies to support projects from plant and animal phylogenetic studies to translational and clinical-based projectsat the GSL. Levy is adjunct faculty in the department of genetics and department of epidemiology at the University of Alabama at Birmingham and serves as an ad hoc reviewer for more than a dozen scientific journals. He received his PhD in biochemistry and completed a postdoctoral fellowship in genetics in 2000 at Emory University in Atlanta, where he set up a microarray facility at the Emory Center for Molecular Medicine. Before joining HudsonAlpha in 2009, Levy was a faculty member at Vanderbilt University Medical Center with appointments in the department of molecular physiology and biophysics and the department of biomedical informatics. He was the founding director of the Vanderbilt Microarray Shared Resource.
Director Biopolymers Facility, Harvard Medical School
Robert Steen is the director of Harvard Medical School’s genomics core facility located within the Department of Genetics in the Longwood Medical Area of Boston. He directs a team of scientists that provide a wide variety of molecular biology services to the faculty at HMS and its sixteen affiliate hospitals and research institutes. Robert has expertise in technology evaluation, process optimization, production oversite, team management and data quality analysis. His core currently focuses on sample preparation and next-generation sequencing for a wide variety of scientific applications. He has over 17 years of experience directing core facilities, three years as director of the HHMI genetics core at HMS and 14 years as current director of the genomics core within the department of genetics at HMS.
In the nine years prior to serving as a core director, Robert worked on and later managed various teams under the direction of Dr. Eric Lander and Dr. Thomas Hudson at the Whitehead Institute/MIT Center for Genome Research, constructing the first comprehensive, genome-wide genetic maps of the mouse and rat. From 1988 to 1991 Robert conducted research on the origins of HIV and SIV in the department of microbiology and molecular genetics at the New England Regional Primate Research Center at Harvard Medical School.
Cory von Wallenstein is the former CTO at Dyn (acquired by Oracle) and a full-time early stage investor and advisor at vw.ventures. His investment thesis is simple and aligns perfectly with Meenta; companies that deliver a customer experience that is 10x faster and easier to use will consistently win over customers. He’s shared his learnings writing for Wired, HuffPost, Inc., TechCrunch, Forbes, as a guest speaker at LAUNCH, Interop, Structure, CIO Summit, and as a guest lecturer at WPI, MIT, and Harvard.
Associate Professor, Boston University
Andrei Hagiu is an Associate Professor at Boston University’s Questrom School of Business, and an active angel investor. He has deep expertise on platform and marketplace businesses which he shares on the Platform Chronicles.
Andrei’s research focuses on multi-sided platforms (e.g. Airbnb, Amazon, eBay, Google, Facebook, PlayStation, TaskRabbit, etc.) and their unique strategic challenges. His work has been published in the Rand Journal of Economics, Management Science, Journal of Economic Perspectives, Journal of Economics & Management Strategy, and the Harvard Business Review.
Andrei holds a PhD in economics from Princeton University and did his undergraduate studies at the Ecole Polytechnique in France. He is a citizen of Romania, France and the United States.
Ending The Isolation
We're making the world’s scientific equipment and clinical tests accessible to everyone.
Meenta is fundamentally changing how scientists can access equipment and their services.”
Assistant Professor, Harvard Business School
Meenta is the amazon of sequencing services.”
Executive Director, UB Genomics and Sequencing Services State University of New York at Buffalo